Smartwatches could help doctors personalize blood transfusions for cancer patients
NCT ID NCT07511829
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for 80 adults with blood cancers like MDS or AML who are starting treatment. Participants wear a smartwatch and answer questionnaires to track their activity, symptoms, and quality of life. The goal is to help doctors better understand when patients need blood transfusions, so care can be more personalized and improve how patients feel during treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Oxford University Hospitals NHS Trust
RECRUITINGOxford, OXFORDSHIRE, OX39DU, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill boost the power of an existing leukemia treatment?
- Can a pill tackle Tough-to-Treat leukemia?
- Can a pill and injection combo beat AML without harsh chemo?
- Can a triple-drug combination tame AML without intensive chemo?
- Personalized dosing may improve stem cell transplant survival in blood cancer patients
- 10,000 DNA samples could reveal hidden genetic triggers for leukemia and lymphoma